Trial Profile
Phase II Multicenter Study Evaluating the Tolerability and Efficacy of RAD001 (Everolimus) in Patients With Relapsed or Metastatic Endometrial Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Dec 2014
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Endometrial cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ENDORAD
- 02 Jul 2012 This trial is recruiting in France.
- 12 May 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
- 12 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.